$CDIOW

Cardio Diagnostics Holdings, Inc.

CIK:0001870144|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue	$ 5,360	$ 7,475	$ 8,040	$ 8,415
Operating expenses
General and administrative	1,144,802	1,296,303	2,600,299	2,574,604
Sales and marketing	190,183	202,850	386,895	391,827
Research and development	162,929	178,536	292,705	297,320
Amortization	5,593	8,485	11,125	53,923
Total operating expenses	1,503,507	1,686,174	3,291,024	3,317,674
Loss from operations	(1,498,147)	(1,678,699)	(3,282,984)	(3,309,259)
Other income (expenses)
Interest income	119	190	237	377
Interest expense	(3,440)	(4,690)	(6,879)	(9,381)
Total other (expenses)	(3,321)	(4,500)	(6,642)	(9,004)
Loss before provision for income taxes	(1,501,468)	(1,683,199)	(3,289,626)	(3,318,263)
Provision for income taxes
Net loss	$ (1,501,468)	$ (1,683,199)	$ (3,289,626)	$ (3,318,263)
Basic and fully diluted income (loss) per common share:
Net loss per common share, basic	$ (0.51)	$ (0.97)	$ (1.13)	$ (1.94)
Net loss per common share, diluted	$ (0.51)	$ (0.97)	$ (1.13)	$ (1.94)
Weighted average common shares outstanding, basic	2,959,469	1,739,045	2,900,452	1,712,741
Weighted average common shares outstanding, fully diluted	2,959,469	1,739,045	2,900,452	1,712,741

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,289,626)	$ (3,318,263)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	88,523	75,441
Amortization	101,570	139,022
Stock-based compensation expense	49,085	61,390
Changes in operating assets and liabilities:
Accounts receivable	4,221	5,685
Prepaid expenses and other current assets	232,590	220,762
Accounts payable and accrued expenses	32,640	(38,937)
Lease liability	(123,579)	(116,666)
NET CASH USED IN OPERATING ACTIVITIES	(2,904,576)	(2,971,566)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(1,760)	(24,483)
Patent costs incurred	(108,725)	(58,649)
NET CASH USED IN INVESTING ACTIVITIES	(110,485)	(83,132)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock, net of issuance costs	3,693,470	3,423,784
Payments of finance agreement	(202,342)	(230,073)
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,491,128	3,193,711
NET INCREASE IN CASH	476,067	139,013
CASH - BEGINNING OF PERIOD	5,110,630	7,827,487
CASH - END OF PERIOD	5,586,697	7,966,500
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest	6,879	9,381
Income taxes

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash	$ 5,586,697	$ 5,110,630
Accounts receivable	3,905	8,126
Prepaid expenses and other current assets	569,357	801,947
Total current assets	6,159,959	5,920,703
Long-term assets
Property and equipment, net	613,352	700,115
Right of use assets, net	169,120	259,565
Deposits	12,850	12,850
Patent costs, net	970,782	873,182
Total assets	7,926,063	7,766,415
Current liabilities
Accounts payable and accrued expenses	130,082	97,442
Lease liability - current	161,667	237,607
Finance agreement payable	67,448	269,790
Total current liabilities	359,197	604,839
Long-term liabilities
Lease liability - long term	140,583	188,222
Total liabilities	499,780	793,061
Stockholders' equity
Preferred stock, $.00001 par value; authorized - 100,000,000 shares; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Common stock, $.00001 par value; authorized - 300,000,000 shares; 2,959,469 and 1,826,051 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	29	18
Additional paid-in capital	39,965,880	36,223,336
Accumulated deficit	(32,539,626)	(29,250,000)
Total stockholders' equity	7,426,283	6,973,354
Total liabilities and stockholders' equity	$ 7,926,063	$ 7,766,415